The emergence of medications like copyright and Semaglutide signifies a remarkable shift in how we approach type 2 diabetes. These groundbreaking therapies belong to a class known as GLP-1 action agonists, which replicate the effects of a natural hormone that manages glucose levels and hunger. First, developed for managing blood sugar, their effect